A study has found that exposure to fine dust can cause psoriasis, a chronic inflammatory skin disease, and worsen its ...

Higher psoriasis (PsO) disease activity is independently associated with impairment in specific sleep domains, but not global ...

Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, ...

A new analysis in JAAD has found that the percentage of U.S. adults with psoriasis has remained essentially unchanged -- 3% -- over about the past decade. But according to investigators, important ...

Dandruff and scalp psoriasis are both unpleasant but very different. Experts share how to tell them apart so you can get the ...

Research on psoriasis touches every aspect of the disease, including the role of nutrition, weight loss, the body’s microbiome, and treatments. While some researchers focus their attention on coming ...

What's The Perfect Climate For Psoriasis? Sign up for the Morning Brief email newsletter to get weekday updates from The Weather Channel and our meteorologists. Everyone's skin reacts differently to ...

AbbVie has announced that the European Commission (EC) has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...

AbbVie ( ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque ...

Risankizumab was associated with sustained complete clearance of psoriasis and showed a favorable safety profile.

Samsung Bioepis and Organon have expanded their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to Pyzchiva, Samsung Bioepis’s Stelara.